Oncothyreon Inc. shares (NASDAQ:ONTY) fell 17.3 percent to $2.30 by Tuesday's close after the company revealed that tecemotide, an immunotherapy it licensed to Merck KGaA, failed to improve overall survival or impact secondary endpoints progression-free survival, time to progression or time to failure in a phase I/II study of 178 patients with stage III non-small-cell lung cancer (NSCLC) conducted for Japanese regulators.